A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
Clinical trial NCT06894212 · RECRUITING
Trial details
- NCT number
- NCT06894212
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-02-28
- Primary completion
- 2026-10-20
- Enrollment
- 522
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.